Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro

View More View Less
  • 1 Clinical Neurosurgery Section, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, and Department of Neurosurgery, Tufts-New England Medical Center, Boston, Massachusetts
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

✓ Lysis of tumor cells by activated cytotoxic lymphocytes requires their recognition of antigens associated with major histocompatibility complex molecules. The authors studied the constitutive expression of Class I and Class II major histocompatibility complex antigens on mouse brain-tumor cells and the capacity of different cytokines and cytokine combinations to alter this expression in vitro. Cells from the murine glioma 26 (GL26), glioma 261 (GL261), and ependymoblastoma A (EpA) cell lines were established in monolayer culture and treated for 48 hours with either alpha interferon, gamma interferon, tumor necrosis factor alpha, tumor necrosis factor alpha plus gamma interferon, or interleukin-2. They were then analyzed by flow cytometry for baseline and cytokine-altered major histocompatibility complex expression.

All cell lines had a similar constitutive major histocompatibility complex pattern with low Class I antigen expression and no detectable Class II antigen expression. Alpha interferon substantially induced and up-regulated Class I antigen expression, but had no effect on Class II antigen expression. Gamma interferon also stimulated up-regulation of Class I antigen expression, generally doubling the anti-Class I antigen fluorescence of treated cells. Its effect on Class II antigen expression was more extensive. In the GL26 and GL261 cell lines, the expression of Class II antigen determinants increased to 12 × and 14 × control values and as many as 75% of cells that had no detectable constitutive expression of Class II antigen expressed this antigen after priming with gamma interferon. The addition of tumor necrosis factor alpha to gamma interferon further increased Class II antigen expression on EpA tumor cells only. Interleukin-2 and tumor necrosis factor alpha alone had no effect on Class I or Class II antigen expression of any cell lines.

It is concluded that Class I and Class II antigen expression in mouse glioma cell lines is induced and enhanced after treatment with certain cytokines in vitro. Use of these cell lines to create in situ primary brain tumors in C57BL/6 mice should provide an excellent animal system to study major histocompatibility complex modulation in brain tumor cells and to examine the potential impact of major histocompatibility complex up-regulation on the response of brain tumors to immunotherapy.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address for Dr. Saris: Tufts-New England Medical Center, 750 Washington Street, Box 178, Boston, Massachusetts 02111.Address reprint requests to: Aytac Akbasak, M.D., National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5D-37, Bethesda, Maryland 20892.
  • 1.

    Ausman JI, , Shapiro WR, & Rall DP: Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 30:23942400, 1970 Ausman JI, Shapiro WR, Rall DP: Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 30:2394–2400, 1970

    • Search Google Scholar
    • Export Citation
  • 2.

    Cameron RB, , McIntosh JK, & Rosenberg SA: Synergistic antitumor effect of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 48:58105817, 1988 Cameron RB, McIntosh JK, Rosenberg SA: Synergistic antitumor effect of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 48:5810–5817, 1988

    • Search Google Scholar
    • Export Citation
  • 3.

    Edidin M: The tissue distribution and cellular location of transplantation antigens, in Kahan BD, & Reisfeld RA (eds): Transplantation Antigens. Markers of Biological Individuality. New York: Academic Press, 1972, pp 125140 Edidin M: The tissue distribution and cellular location of transplantation antigens, in Kahan BD, Reisfeld RA (eds): Transplantation Antigens. Markers of Biological Individuality. New York: Academic Press, 1972, pp 125–140

    • Search Google Scholar
    • Export Citation
  • 4.

    Fierz W, , Endler B, & Reske K, et al: Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 134:37853793, 1985 Fierz W, Endler B, Reske K, et al: Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 134:3785–3793, 1985

    • Search Google Scholar
    • Export Citation
  • 5.

    Fransen L, , Van der Heyden J, & Ruysschaert R, et al: Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 22:419426, 1986 Fransen L, Van der Heyden J, Ruysschaert R, et al: Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 22:419–426, 1986

    • Search Google Scholar
    • Export Citation
  • 6.

    Mahaley MS Jr, , Steinbok P, & Aronin P, et al: Immunobiology of primary intracranial tumors. Part 4: Levamisole as an immune stimulant in patients and in the ASV glioma model. J Neurosurg 54:220227, 1981 Mahaley MS Jr, Steinbok P, Aronin P, et al: Immunobiology of primary intracranial tumors. Part 4: Levamisole as an immune stimulant in patients and in the ASV glioma model. J Neurosurg 54:220–227, 1981

    • Search Google Scholar
    • Export Citation
  • 7.

    Mahaley MS Jr, , Urso MB, & Whaley RA, et al: Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 63:719725, 1985 Mahaley MS Jr, Urso MB, Whaley RA, et al: Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 63:719–725, 1985

    • Search Google Scholar
    • Export Citation
  • 8.

    McCutcheon IE, , Baranco RA, & Katz DA, et al: Adoptive immunotherapy of intracerebral metastases in mice. J Neurosurg 72:102109, 1990 McCutcheon IE, Baranco RA, Katz DA, et al: Adoptive immunotherapy of intracerebral metastases in mice. J Neurosurg 72:102–109, 1990

    • Search Google Scholar
    • Export Citation
  • 9.

    Mitchell MS: Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7:17011709, 1989 Mitchell MS: Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7:1701–1709, 1989

    • Search Google Scholar
    • Export Citation
  • 10.

    Mulé JJ, , Yang J, & Shu S, et al: The anti-tumor efficacy of lymphokine activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 136:38993909, 1989 Mulé JJ, Yang J, Shu S, et al: The anti-tumor efficacy of lymphokine activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 136:3899–3909, 1989

    • Search Google Scholar
    • Export Citation
  • 11.

    Neuwelt EA, , Clark K, & Kirkpatrick JB, et al: Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: a toxicity study. Ann Neurol 4:307312, 1978 Neuwelt EA, Clark K, Kirkpatrick JB, et al: Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: a toxicity study. Ann Neurol 4:307–312, 1978

    • Search Google Scholar
    • Export Citation
  • 12.

    Piguet V, , Carrel S, & Diserens AC, et al: Heterogeneity of the induction of HLA-DR expression by human immune interferon on glioma cell lines and their clones. JNCI 76:223228, 1986 Piguet V, Carrel S, Diserens AC, et al: Heterogeneity of the induction of HLA-DR expression by human immune interferon on glioma cell lines and their clones. JNCI 76:223–228, 1986

    • Search Google Scholar
    • Export Citation
  • 13.

    Piguet V, , Diserens AC, & Carrel S, et al: The immunobiology of human gliomas. Springer Semin Immunopathol 8:111127, 1985 Piguet V, Diserens AC, Carrel S, et al: The immunobiology of human gliomas. Springer Semin Immunopathol 8:111–127, 1985

    • Search Google Scholar
    • Export Citation
  • 14.

    Pulver M, , Carrel S, & Mach JP, et al: Cultured human fetal astrocytes can be induced by interferon-γ to express HLA-DR. J Neuroimmunol 14:123133, 1987 Pulver M, Carrel S, Mach JP, et al: Cultured human fetal astrocytes can be induced by interferon-γ to express HLA-DR. J Neuroimmunol 14:123–133, 1987

    • Search Google Scholar
    • Export Citation
  • 15.

    Rosenberg SA, , Lotze MT, & Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889897, 1987 Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897, 1987

    • Search Google Scholar
    • Export Citation
  • 16.

    Rosenberg SA, , Schwarz SL, & Spiess PJ: Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alpha interferon, and tumor infiltrating lymphocytes. JNCI 80:13931397, 1988 Rosenberg SA, Schwarz SL, Spiess PJ: Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alpha interferon, and tumor infiltrating lymphocytes. JNCI 80:1393–1397, 1988

    • Search Google Scholar
    • Export Citation
  • 17.

    Saito T, , Tanaka R, & Yoshida S, et al: Immunohistochemical analysis of tumor-infiltrating lymphocytes and major histocompatibility antigens in human gliomas and metastatic brain tumors. Surg Neurol 29:435442, 1988 Saito T, Tanaka R, Yoshida S, et al: Immunohistochemical analysis of tumor-infiltrating lymphocytes and major histocompatibility antigens in human gliomas and metastatic brain tumors. Surg Neurol 29:435–442, 1988

    • Search Google Scholar
    • Export Citation
  • 18.

    Saris SC, , Patronas NJ, & Rosenberg SA, et al: The effect of intravenous interleukin-2 on brain water content. J Neurosurg 71:169174, 1989 Saris SC, Patronas NJ, Rosenberg SA, et al: The effect of intravenous interleukin-2 on brain water content. J Neurosurg 71:169–174, 1989

    • Search Google Scholar
    • Export Citation
  • 19.

    Saris SC, , Rosenberg SA, & Friedman RB, et al: Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 69:2934, 1988 Saris SC, Rosenberg SA, Friedman RB, et al: Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 69:29–34, 1988

    • Search Google Scholar
    • Export Citation
  • 20.

    Spiess PJ, , Yang JC, & Rosenberg SA: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. JNCI 79:10671075, 1987 Spiess PJ, Yang JC, Rosenberg SA: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. JNCI 79:1067–1075, 1987

    • Search Google Scholar
    • Export Citation
  • 21.

    Topalian SL, , Solomon D, & Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 6:839853, 1988 Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 6:839–853, 1988

    • Search Google Scholar
    • Export Citation
  • 22.

    Weber JS, , Jay G, & Tanaka K, et al: Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC Class I gene transfection. J Exp Med 166:17161733, 1987 Weber JS, Jay G, Tanaka K, et al: Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC Class I gene transfection. J Exp Med 166:1716–1733, 1987

    • Search Google Scholar
    • Export Citation
  • 23.

    Weber JS, & Rosenberg SA: Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 48:58185824, 1988 Weber JS, Rosenberg SA: Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 48:5818–5824, 1988

    • Search Google Scholar
    • Export Citation
  • 24.

    Wong GHW, , Bartlett PF, & Clark-Lewis I, et al: Inducible expression of H-2 and la antigens on brain cells. Nature 310:688691, 1984 Wong GHW, Bartlett PF, Clark-Lewis I, et al: Inducible expression of H-2 and la antigens on brain cells. Nature 310:688–691, 1984

    • Search Google Scholar
    • Export Citation
  • 25.

    Wong GHW, , Bartlett PF, & Clark-Lewis I, et al: Interferon gamma induces the expression of H-2 and Ia antigens on brain cells. J Neuroimmunol 7:255258, 1985 Wong GHW, Bartlett PF, Clark-Lewis I, et al: Interferon gamma induces the expression of H-2 and Ia antigens on brain cells. J Neuroimmunol 7:255–258, 1985

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 427 237 18
Full Text Views 202 16 1
PDF Downloads 90 13 1
EPUB Downloads 0 0 0